evitria is an established, global antibody expression service provider that specializes in CHO-based transient expression of recombinant antibodies and proteins. We are based in Zurich, Switzerland with offices in Cambridge, MA; San Diego, CA, and Cambridge, UK.

Recombinant Antibody Production Services

Since 2010, we have preformed more than 80,000 transfections, expressed more than 19,000 proteins and purified more than 13,000 antibodies. We have been supporting customers globally from the Americas, Europe, Asia and Australia ranging from academic laboratories, small biotech start-ups to global biopharmaceutical companies. Whether you are looking to entrust a partner with your complete antibody prodcution or to manage capacity bottlenecks with single projects, you can benefit from evitria’s expertise.

This unique expertise includes the following capabilities:

Isotype switching
Chimerization
Glyco-engineering
Bispecific and trispecific antibodies
Fusion antibodies including Fc fusion proteins

Why evitria:

fast, reliable and flexible project execution
industry’s highest quality standards with consistently low endotoxin levels and possibility of guaranteed purity
unique focus on recombinant antibody production
outstanding experience and unparalleled expertise

Expression services

Recombinant antibodies

evitria offers recombinant antibody production in CHO cell culture. Recombinant antibody expression in CHO cells allows a fast production with assurance of the highest quality.

With no lead times or wait for production slots, our clients benefit from a fast project execution and we are up to months faster than antibody suppliers relying on hybridoma cells. At evitria, we are able to deliver antibodies as fast as ~5 weeks.

Take advantage of our services by outsourcing your transient recombinant antibody expression to pursue single projects or relieve capacity bottlenecks.

Afucosylated antibodies for ADCC enhancement

evitria holds an exclusive licensing partnership to offer afucosylation via ProBioGen’s GlymaxX® technology for your transient antibody expression needs.

Afucosylation is a way to artificially decrease fucose content and increase ADCC. Higher antibody dependent cellular cytotoxicity in therapeutic antibodies elevates the killing activity against tumorigenic or infected cells. Therefore, afucosylated antibodies are promising drug candidates.

Other Proteins

If your needs extend beyond antibodies, evitria’s platform can be adapted to transiently express any secreted protein (e.g. scFvs, soluble extracellular domains, cytokines, and viral proteins among many others).